ClinicalTrials.gg
CompletedNCT03188510Updated Jan 25, 2024Results posted

A Study of Two Different Formulations of LY3074828 in Healthy Participants

A Phase 1 interventional study of LY3074828 in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-25.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to look at the amount of the study drug, LY3074828, that gets into the blood stream and how long it takes the body to get rid of LY3074828 when given as different formulations. The tolerability of LY3074828 will also be evaluated and information about any side effects experienced will be collected.

Screening is required within 28 days prior to the start of the study. For each participant, the total duration of the clinical trial will be approximately 13 weeks, not including screening.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

Exclusion Criteria:

  • Must not have an average weekly alcohol intake that exceeds 21 units/week (males) and 14 units/week (females)
  • Must not show evidence of active or latent tuberculosis (TB)
  • Must not have received (s) (including attenuated live vaccines and those administered intranasally) within 1 month of screening, or intend to during the study
  • Must not have been treated with within 1 month of screening, or intend to during the study
  • Must not be
  • Must not have received treatment with biologic agents (e.g. monoclonal antibodies, including marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior to Day 1
  • Must not have significant allergies to humanised monoclonal antibodies
  • Must not have multiple or severe drug allergies, or intolerance to topical corticosteroids, or sever post treatment reactions
  • Must not have had lymphoma, leukemia, or any within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of disease for 3 years
  • Must not have had breast cancer within the past 10 years
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    Reference: 250 mg LY3074828

    250 mg LY3074828 lyophilized formulation administered subcutaneously (SC) as 3 injections

    Biological: LY3074828

  • Experimental
    Test 1: 250 mg LY3074828

    250 mg LY3074828 solution formulation administered as SC injections in two prefilled syringes

    Biological: LY3074828

  • Experimental
    Test 2: 500 mg LY3074828

    500 mg LY3074828 solution formulation administered as SC injections in four prefilled syringes

    Biological: LY3074828

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Dose-normalized Area Under the Serum Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (DN-AUC[0-tlast]) of LY3074828

    PK: Dose-normalized Area Under the Serum Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (DN-AUC\[0-tlast\]) of LY3074828 was evaluated. Unit of measure expansion: microgram\*day per milliliter per milligram (µg\*day/mL/mg).

    Time frame: Predose; 2, 6, 24, 72, 168, 240, 336, 504, 672, 1008, 1344, 1680 and 2016 hours postdose

  2. PK: Dose-normalized Area Under the Serum Concentration-Time Curve From Time Zero to Infinity (DN-AUC[0-∞]) of LY3074828

    PK: Dose-normalized Area Under the Serum Concentration-Time Curve From Time Zero to Infinity (DN-AUC\[0-∞\]) of LY3074828 was evaluated.

    Time frame: Predose; 2, 6, 24, 72, 168, 240, 336, 504, 672, 1008, 1344, 1680 and 2016 hours postdose

Secondary outcomes

  1. Number of Participants With Treatment Emergent Anti-Drug Antibodies (TE-ADA)

    Number of participants with positive treatment emergent anti-drug antibodies was summarized by treatment group. A treatment-emergent ADA (TEADA) was defined as: having a negative ADA at baseline and an ADA titer greater than or equal to 1:20 (that is (i.e.), greater than 2-fold from the minimal required dilution of 1:10) any time post baseline (i.e., treatment-induced); or a 4-fold or greater change in ADA titer from baseline for participants that had a detectable ADA titer at baseline (i.e., treatment boosted).

    Time frame: Predose Day 1 Through Day 85

07

Results

Posted Jan 25, 2024

Participant flow

Participant flow — Overall Study
MilestoneReference: 250 mg LY3074828Test 1: 250 mg LY3074828Test 2: 500 mg LY3074828
Started181818
Received at least 1 dose of study drug181818
Completed181718
Not completed010
Withdrew: Inappropriate behavior with site staff010

Outcome measures

PrimaryPharmacokinetics (PK): Dose-normalized Area Under the Serum Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (DN-AUC[0-tlast]) of LY3074828

PK: Dose-normalized Area Under the Serum Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (DN-AUC\[0-tlast\]) of LY3074828 was evaluated. Unit of measure expansion: microgram\*day per milliliter per milligram (µg\*day/mL/mg).

Time frame:
Predose; 2, 6, 24, 72, 168, 240, 336, 504, 672, 1008, 1344, 1680 and 2016 hours postdose
Reported as:
Geometric mean · µg*day/mL/mg
Pharmacokinetics (PK): Dose-normalized Area Under the Serum Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (DN-AUC[0-tlast]) of LY3074828
µg*day/mL/mgReference: 250 mg LY3074828Test 1: 250 mg LY3074828Test 2: 500 mg LY3074828
Pharmacokinetics (PK): Dose-normalized Area Under the Serum Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (DN-AUC[0-tlast]) of LY30748281.06 ± 271.03 ± 401.04 ± 32
Statistical analysis
  • Reference: 250 mg LY3074828 vs Test 1: 250 mg LY3074828 · Ratio of geometric least squares means: 0.971 · 90% CI 0.805 to 1.17
  • Test 1: 250 mg LY3074828 vs Test 2: 500 mg LY3074828 · Ratio of geometric least squares means: 1.01 · 90% CI 0.841 to 1.22
  • Reference: 250 mg LY3074828 vs Test 2: 500 mg LY3074828 · Ratio of geometric least squares means: 0.985 · 90% CI 0.819 to 1.18
PrimaryPK: Dose-normalized Area Under the Serum Concentration-Time Curve From Time Zero to Infinity (DN-AUC[0-∞]) of LY3074828

PK: Dose-normalized Area Under the Serum Concentration-Time Curve From Time Zero to Infinity (DN-AUC\[0-∞\]) of LY3074828 was evaluated.

Time frame:
Predose; 2, 6, 24, 72, 168, 240, 336, 504, 672, 1008, 1344, 1680 and 2016 hours postdose
Reported as:
Geometric mean · µg.day/mL/mg
PK: Dose-normalized Area Under the Serum Concentration-Time Curve From Time Zero to Infinity (DN-AUC[0-∞]) of LY3074828
µg.day/mL/mgReference: 250 mg LY3074828Test 1: 250 mg LY3074828Test 2: 500 mg LY3074828
PK: Dose-normalized Area Under the Serum Concentration-Time Curve From Time Zero to Infinity (DN-AUC[0-∞]) of LY30748281.07 ± 271.05 ± 401.05 ± 32
Statistical analysis
  • Reference: 250 mg LY3074828 vs Test 1: 250 mg LY3074828 · Ratio of geometric least squares means: 0.978 · 90% CI 0.811 to 1.18
  • Test 1: 250 mg LY3074828 vs Test 2: 500 mg LY3074828 · Ratio of geometric least squares means: 1.00 · 90% CI 0.833 to 1.21
  • Reference: 250 mg LY3074828 vs Test 2: 500 mg LY3074828 · Ratio of geometric least squares means: 0.982 · 90% CI 0.817 to 1.18
SecondaryNumber of Participants With Treatment Emergent Anti-Drug Antibodies (TE-ADA)

Number of participants with positive treatment emergent anti-drug antibodies was summarized by treatment group. A treatment-emergent ADA (TEADA) was defined as: having a negative ADA at baseline and an ADA titer greater than or equal to 1:20 (that is (i.e.), greater than 2-fold from the minimal required dilution of 1:10) any time post baseline (i.e., treatment-induced); or a 4-fold or greater change in ADA titer from baseline for participants that had a detectable ADA titer at baseline (i.e., treatment boosted).

Time frame:
Predose Day 1 Through Day 85
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Anti-Drug Antibodies (TE-ADA)
ParticipantsReference: 250 mg LY3074828Test 1: 250 mg LY3074828Test 2: 500 mg LY3074828
Number of Participants With Treatment Emergent Anti-Drug Antibodies (TE-ADA)767

Adverse events

Collected over Up to 85 days after administration of study drug. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Reference: 250 mg LY30748280/18 (0%)0/18 (0%)16/18 (88.9%)
Test 1: 250 mg LY30748280/18 (0%)0/18 (0%)15/18 (83.3%)
Test 2: 500 mg LY30748280/18 (0%)0/18 (0%)18/18 (100%)
Most frequent other events
Showing 10 of 17
Most frequent other events
EventReference: 250 mg LY3074828Test 1: 250 mg LY3074828Test 2: 500 mg LY3074828
Injection site reactionGeneral disorders15/1815/1818/18
Injection site haemorrhageGeneral disorders3/181/183/18
ConstipationGastrointestinal disorders0/180/181/18
DiarrhoeaGastrointestinal disorders1/180/180/18
NauseaGastrointestinal disorders1/181/180/18
ToothacheGastrointestinal disorders0/181/180/18
Feeling hotGeneral disorders1/180/180/18
Upper respiratory tract infectionInfections and infestations0/180/181/18
Viral upper respiratory tract infectionInfections and infestations0/180/181/18
Arthropod biteInjury, poisoning and procedural complications0/180/181/18

Baseline characteristics

All enrolled participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Reference: 250 mg LY3074828Test 1: 250 mg LY3074828Test 2: 500 mg LY3074828Total
Mean41.6 ± 12.642.1 ± 11.042.5 ± 10.342.0 ± 11.1
Sex: Female, Male
Sex: Female, Male(Participants)Reference: 250 mg LY3074828Test 1: 250 mg LY3074828Test 2: 500 mg LY3074828Total
Female108826
Male8101028
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Reference: 250 mg LY3074828Test 1: 250 mg LY3074828Test 2: 500 mg LY3074828Total
Hispanic or Latino44614
Not Hispanic or Latino14141240
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Reference: 250 mg LY3074828Test 1: 250 mg LY3074828Test 2: 500 mg LY3074828Total
American Indian or Alaska Native0000
Asian0011
Native Hawaiian or Other Pacific Islander0000
Black or African American910726
White98926
More than one race0011
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(Participants)Reference: 250 mg LY3074828Test 1: 250 mg LY3074828Test 2: 500 mg LY3074828Total
United States18181854
08

Study locations

1 site
  • Covance
    Dallas, Texas 75247, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2017 to primary completion in Nov 2017, 4 months.

Results were first posted in Jan 2024, 6 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2017
First posted
Jun 15, 2017
StartActual
Jun 30, 2017
Primary completionActual
Nov 27, 2017
CompletionActual
Nov 27, 2017
Results first posted
Jan 25, 2024
Last update
Jan 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03188510
Responsible party
Sponsor
First posted
Jun 15, 2017
Start date
Jun 30, 2017
Primary completion
Nov 27, 2017
Completion
Nov 27, 2017
Results posted
Jan 25, 2024
Last update
Jan 25, 2024

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mirikizumab

Start the discussion